About Travecta Therapeutics

Travecta Therapeutics is a company that develops novel chemistry for delivery of therapies to the brain.Travecta is based on the research of Prof. David Silver and leverages a discovery platform to identify, simplify and categorize small molecules for enabling their transport across the blood-brain barrier.

Contact Us

Fundamental Discovery has resulted in Our Revolutionary Platform for Delivering Drugs more Effectively into the Brain.

Management Team

Prof David L. Silver

Scientific Founder

  • Professor and Deputy Director of the Signature Research Program in Cardiovascular & Metabolic Disorders at Duke-NUS Medical School, Singapore.
  • Research focus on molecular nutrition and role of lipids in brain and eye function and health. Discoverer of the Mfsd2a-LPC pathway.
  • Doctorate in Genetics from University of Michigan and postdoctoral training in cardiovascular and lipid research at Columbia University. Held tenure-track faculty appointments at Columbia University and the Albert Einstein College of Medicine, USA.

Dr. Mahmood Ahmed

Scientific Founder

  • Drug Discovery and Development expert, with 14 years of Pharma experience, the majority of which has been spent in the CNS field.
  • Established Drug Discovery capability, lead multiple drug discovery projects, developed projects to key milestones, achieving desired outcomes and delivering multiple assets for clinical development.
  • Doctorate in  Synthetic Chemistry from Imperial College, joined GSK as a Medicinal Chemist, building in depth knowledge of DMPK, disease biology, and pharmacology. Member of R&D site leadership team.

Dr. Michael Shleifer

Founder, Singapore

  • Founding Managing Partner of SPRIM with 20 year experience in the healthcare sector, overseeing hundreds of innovation projects every year, and around 12 new commercial models per annum.
  • Long experience in Pharmaceuticals and Medtech.
  • Doctorate from Universite Rene Descartes Paris V and a Master Political Science from Sciences Po Paris.

Laurent Benissan

Founder, Singapore

  • Founder of Silhouette Lift, an innovative medical device company in the aesthetic field. Started the company in 2007 and developed a cutting edge technology used for minimally invasive facial rejuvenation. In 2014, Silhouette Lift was sold to Sinclair IS Pharma, a public company in the UK.
  • Spent the first 15 years of his career in investment banking, working for Merrill Lynch and other international firms.
  • Master in management from HEC business school in France.